Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 73-78

  Seko, Naotsugu ^a   Oue, Naohide ^a   Noguchi, Tsuyoshi ^b   Sentani, Kazuhiro ^a   Sakamoto, Naoya ^a   Hinoi, Takao ^a   Okajima, Masazumi ^a   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Olfactomedin 4; OLFM4; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; OLFACTOMEDIN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

EID: 77955732927     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000013     Document Type: Article

References (20)

1. Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618, 2005.
2. Oue N, Kuniyasu H, Noguchi T, et al: Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 72: 371-380, 2007.
3. Kobayashi T, Hino S, Oue N, Asahara T, Zollo M, Yasui W and Kikuchi A: Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol 26: 898-911, 2006.
4. Oue N, Hamai Y, Mitani Y, et al: Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis and carcinogenesis by serial analysis of gene expression. Cancer Res 64: 2397-2405, 2004.
5. Aung PP, Oue N, Mitani Y, et al: Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25: 2546-2557, 2006.
6. Zhang J, Liu WL, Tang DC, et al: Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene 283: 83-93, 2002.
7. Zhang X, Huang Q, Yang Z, Li Y and Li CY: GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 64: 2474-2481, 2004.
8. Liu W, Zhu J, Cao L and Rodgers GP: Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology 51: 157-165, 2007.
9. Oue N, Sentani K, Noguchi T, et al: Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer 125: 2383-2392, 2009.
10. Koshida S, Kobayashi D, Moriai R, Tsuji N and Watanabe N: Specific overexpression of OLFM4 (GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci 98: 315-320, 2007.
11. Conrotto P, Roesli C, Rybak J, et al: Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 123: 2856-2864, 2008.
12. Van der Flier LG, Haegebarth A, Stange DE, van de WeteringM and Clevers H: OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 137: 15-17, 2009.
13. Liu W, Liu Y, Zhu J, Wright E, Ding I and Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res 14: 1041-1049, 2008.
14. Sobin LH and Wittekind CH (eds): TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, New York, pp 65-68, 2002.
15. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
16. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
17. Kurokawa S, Arimura Y, Yamamoto H, et al: Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut 54: 1751-1758, 2005.
18. Takaoka M, Naomoto Y, Ohkawa T, et al: Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 83: 613-622, 2003.
19. Kuniyasu H, Yasui W, Shinohara H, et al: Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 157: 1523-1535, 2000.
20. Shinozaki S, Nakamura T, Iimura M, et al: Upregulation of Reg 1 alpha and GW112 in the epithelium of inflamed colonic mucosa. Gut 48: 623-629, 2001.